The global Therapeutic Radioligands market was valued at US$ 1043 million in 2023 and is anticipated to reach US$ 4471.9 million by 2030, witnessing a CAGR of 17.4% during the forecast period 2024-2030.

Therapeutic Radioligands Market

Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.

This report aims to provide a comprehensive presentation of the global market for Therapeutic Radioligands, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Radioligands.

Report Scope

The Therapeutic Radioligands market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Therapeutic Radioligands market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Therapeutic Radioligands companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Therapeutic Radioligands Market Report

Report Metric	Details
Report Name	Therapeutic Radioligands Market
Accounted market size in 2023	US$ 1043 million
Forecasted market size in 2030	US$ 4471.9 million
CAGR	17.4%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Beta-emitting Targeted Alpha Therapy
Segment by Application	Solid Tumor Non Hodgkin Lymphoma
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapeutic Radioligands companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Therapeutic Radioligands Market growing?

Ans: The Therapeutic Radioligands Market witnessing a CAGR of 17.4% during the forecast period 2024-2030.

What is the Therapeutic Radioligands Market size in 2030?

Ans: The Therapeutic Radioligands Market size in 2030 will be US$ 4471.9 million.

Who are the main players in the Therapeutic Radioligands Market report?

Ans: The main players in the Therapeutic Radioligands Market are Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals

What are the Application segmentation covered in the Therapeutic Radioligands Market report?

Ans: The Applications covered in the Therapeutic Radioligands Market report are Solid Tumor, Non Hodgkin Lymphoma

What are the Type segmentation covered in the Therapeutic Radioligands Market report?

Ans: The Types covered in the Therapeutic Radioligands Market report are Beta-emitting, Targeted Alpha Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Therapeutic Radioligands Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Beta-emitting

1.2.3 Targeted Alpha Therapy

1.3 Market by Application

1.3.1 Global Therapeutic Radioligands Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Solid Tumor

1.3.3 Non Hodgkin Lymphoma

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Therapeutic Radioligands Market Perspective (2019-2030)

2.2 Therapeutic Radioligands Growth Trends by Region

2.2.1 Global Therapeutic Radioligands Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Therapeutic Radioligands Historic Market Size by Region (2019-2024)

2.2.3 Therapeutic Radioligands Forecasted Market Size by Region (2025-2030)

2.3 Therapeutic Radioligands Market Dynamics

2.3.1 Therapeutic Radioligands Industry Trends

2.3.2 Therapeutic Radioligands Market Drivers

2.3.3 Therapeutic Radioligands Market Challenges

2.3.4 Therapeutic Radioligands Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Therapeutic Radioligands Players by Revenue

3.1.1 Global Top Therapeutic Radioligands Players by Revenue (2019-2024)

3.1.2 Global Therapeutic Radioligands Revenue Market Share by Players (2019-2024)

3.2 Global Therapeutic Radioligands Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Therapeutic Radioligands Revenue

3.4 Global Therapeutic Radioligands Market Concentration Ratio

3.4.1 Global Therapeutic Radioligands Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Therapeutic Radioligands Revenue in 2023

3.5 Therapeutic Radioligands Key Players Head office and Area Served

3.6 Key Players Therapeutic Radioligands Product Solution and Service

3.7 Date of Enter into Therapeutic Radioligands Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Therapeutic Radioligands Breakdown Data by Type

4.1 Global Therapeutic Radioligands Historic Market Size by Type (2019-2024)

4.2 Global Therapeutic Radioligands Forecasted Market Size by Type (2025-2030)

5 Therapeutic Radioligands Breakdown Data by Application

5.1 Global Therapeutic Radioligands Historic Market Size by Application (2019-2024)

5.2 Global Therapeutic Radioligands Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Therapeutic Radioligands Market Size (2019-2030)

6.2 North America Therapeutic Radioligands Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Therapeutic Radioligands Market Size by Country (2019-2024)

6.4 North America Therapeutic Radioligands Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Therapeutic Radioligands Market Size (2019-2030)

7.2 Europe Therapeutic Radioligands Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Therapeutic Radioligands Market Size by Country (2019-2024)

7.4 Europe Therapeutic Radioligands Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Therapeutic Radioligands Market Size (2019-2030)

8.2 Asia-Pacific Therapeutic Radioligands Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Therapeutic Radioligands Market Size by Region (2019-2024)

8.4 Asia-Pacific Therapeutic Radioligands Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Therapeutic Radioligands Market Size (2019-2030)

9.2 Latin America Therapeutic Radioligands Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Therapeutic Radioligands Market Size by Country (2019-2024)

9.4 Latin America Therapeutic Radioligands Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Therapeutic Radioligands Market Size (2019-2030)

10.2 Middle East & Africa Therapeutic Radioligands Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Therapeutic Radioligands Market Size by Country (2019-2024)

10.4 Middle East & Africa Therapeutic Radioligands Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bayer

11.1.1 Bayer Company Detail

11.1.2 Bayer Business Overview

11.1.3 Bayer Therapeutic Radioligands Introduction

11.1.4 Bayer Revenue in Therapeutic Radioligands Business (2019-2024)

11.1.5 Bayer Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Therapeutic Radioligands Introduction

11.2.4 Novartis Revenue in Therapeutic Radioligands Business (2019-2024)

11.2.5 Novartis Recent Development

11.3 Lantheus

11.3.1 Lantheus Company Detail

11.3.2 Lantheus Business Overview

11.3.3 Lantheus Therapeutic Radioligands Introduction

11.3.4 Lantheus Revenue in Therapeutic Radioligands Business (2019-2024)

11.3.5 Lantheus Recent Development

11.4 Aurobindo Pharma

11.4.1 Aurobindo Pharma Company Detail

11.4.2 Aurobindo Pharma Business Overview

11.4.3 Aurobindo Pharma Therapeutic Radioligands Introduction

11.4.4 Aurobindo Pharma Revenue in Therapeutic Radioligands Business (2019-2024)

11.4.5 Aurobindo Pharma Recent Development

11.5 Mundipharma

11.5.1 Mundipharma Company Detail

11.5.2 Mundipharma Business Overview

11.5.3 Mundipharma Therapeutic Radioligands Introduction

11.5.4 Mundipharma Revenue in Therapeutic Radioligands Business (2019-2024)

11.5.5 Mundipharma Recent Development

11.6 China Isotope & Radiation

11.6.1 China Isotope & Radiation Company Detail

11.6.2 China Isotope & Radiation Business Overview

11.6.3 China Isotope & Radiation Therapeutic Radioligands Introduction

11.6.4 China Isotope & Radiation Revenue in Therapeutic Radioligands Business (2019-2024)

11.6.5 China Isotope & Radiation Recent Development

11.7 Curium Pharmaceuticals

11.7.1 Curium Pharmaceuticals Company Detail

11.7.2 Curium Pharmaceuticals Business Overview

11.7.3 Curium Pharmaceuticals Therapeutic Radioligands Introduction

11.7.4 Curium Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024)

11.7.5 Curium Pharmaceuticals Recent Development

11.8 Gilead Sciences

11.8.1 Gilead Sciences Company Detail

11.8.2 Gilead Sciences Business Overview

11.8.3 Gilead Sciences Therapeutic Radioligands Introduction

11.8.4 Gilead Sciences Revenue in Therapeutic Radioligands Business (2019-2024)

11.8.5 Gilead Sciences Recent Development

11.9 Clarity Pharmaceuticals

11.9.1 Clarity Pharmaceuticals Company Detail

11.9.2 Clarity Pharmaceuticals Business Overview

11.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Introduction

11.9.4 Clarity Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024)

11.9.5 Clarity Pharmaceuticals Recent Development

11.10 Curasight

11.10.1 Curasight Company Detail

11.10.2 Curasight Business Overview

11.10.3 Curasight Therapeutic Radioligands Introduction

11.10.4 Curasight Revenue in Therapeutic Radioligands Business (2019-2024)

11.10.5 Curasight Recent Development

11.11 Nordic Nanovector

11.11.1 Nordic Nanovector Company Detail

11.11.2 Nordic Nanovector Business Overview

11.11.3 Nordic Nanovector Therapeutic Radioligands Introduction

11.11.4 Nordic Nanovector Revenue in Therapeutic Radioligands Business (2019-2024)

11.11.5 Nordic Nanovector Recent Development

11.12 Philogen

11.12.1 Philogen Company Detail

11.12.2 Philogen Business Overview

11.12.3 Philogen Therapeutic Radioligands Introduction

11.12.4 Philogen Revenue in Therapeutic Radioligands Business (2019-2024)

11.12.5 Philogen Recent Development

11.13 RadioMedix

11.13.1 RadioMedix Company Detail

11.13.2 RadioMedix Business Overview

11.13.3 RadioMedix Therapeutic Radioligands Introduction

11.13.4 RadioMedix Revenue in Therapeutic Radioligands Business (2019-2024)

11.13.5 RadioMedix Recent Development

11.14 Telix Pharmaceuticals

11.14.1 Telix Pharmaceuticals Company Detail

11.14.2 Telix Pharmaceuticals Business Overview

11.14.3 Telix Pharmaceuticals Therapeutic Radioligands Introduction

11.14.4 Telix Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024)

11.14.5 Telix Pharmaceuticals Recent Development

11.15 Orano Med

11.15.1 Orano Med Company Detail

11.15.2 Orano Med Business Overview

11.15.3 Orano Med Therapeutic Radioligands Introduction

11.15.4 Orano Med Revenue in Therapeutic Radioligands Business (2019-2024)

11.15.5 Orano Med Recent Development

11.16 Actinium Pharmaceuticals

11.16.1 Actinium Pharmaceuticals Company Detail

11.16.2 Actinium Pharmaceuticals Business Overview

11.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Introduction

11.16.4 Actinium Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024)

11.16.5 Actinium Pharmaceuticals Recent Development

11.17 Y-mAbs Therapeutics

11.17.1 Y-mAbs Therapeutics Company Detail

11.17.2 Y-mAbs Therapeutics Business Overview

11.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Introduction

11.17.4 Y-mAbs Therapeutics Revenue in Therapeutic Radioligands Business (2019-2024)

11.17.5 Y-mAbs Therapeutics Recent Development

11.18 Fusion Pharmaceuticals

11.18.1 Fusion Pharmaceuticals Company Detail

11.18.2 Fusion Pharmaceuticals Business Overview

11.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Introduction

11.18.4 Fusion Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024)

11.18.5 Fusion Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

China Isotope & Radiation

Curium Pharmaceuticals

Gilead Sciences

Clarity Pharmaceuticals

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

List of Tables

Table 1. Global Therapeutic Radioligands Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Beta-emitting

Table 3. Key Players of Targeted Alpha Therapy

Table 4. Global Therapeutic Radioligands Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Therapeutic Radioligands Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Therapeutic Radioligands Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Therapeutic Radioligands Market Share by Region (2019-2024)

Table 8. Global Therapeutic Radioligands Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Therapeutic Radioligands Market Share by Region (2025-2030)

Table 10. Therapeutic Radioligands Market Trends

Table 11. Therapeutic Radioligands Market Drivers

Table 12. Therapeutic Radioligands Market Challenges

Table 13. Therapeutic Radioligands Market Restraints

Table 14. Global Therapeutic Radioligands Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Therapeutic Radioligands Market Share by Players (2019-2024)

Table 16. Global Top Therapeutic Radioligands Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Radioligands as of 2023)

Table 17. Ranking of Global Top Therapeutic Radioligands Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Therapeutic Radioligands Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Therapeutic Radioligands Product Solution and Service

Table 21. Date of Enter into Therapeutic Radioligands Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Therapeutic Radioligands Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Therapeutic Radioligands Revenue Market Share by Type (2019-2024)

Table 25. Global Therapeutic Radioligands Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Therapeutic Radioligands Revenue Market Share by Type (2025-2030)

Table 27. Global Therapeutic Radioligands Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Therapeutic Radioligands Revenue Market Share by Application (2019-2024)

Table 29. Global Therapeutic Radioligands Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Therapeutic Radioligands Revenue Market Share by Application (2025-2030)

Table 31. North America Therapeutic Radioligands Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Therapeutic Radioligands Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Therapeutic Radioligands Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Therapeutic Radioligands Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Therapeutic Radioligands Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Therapeutic Radioligands Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Therapeutic Radioligands Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Therapeutic Radioligands Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Therapeutic Radioligands Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Therapeutic Radioligands Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Therapeutic Radioligands Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Therapeutic Radioligands Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Therapeutic Radioligands Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Therapeutic Radioligands Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Therapeutic Radioligands Market Size by Country (2025-2030) & (US$ Million)

Table 46. Bayer Company Detail

Table 47. Bayer Business Overview

Table 48. Bayer Therapeutic Radioligands Product

Table 49. Bayer Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 50. Bayer Recent Development

Table 51. Novartis Company Detail

Table 52. Novartis Business Overview

Table 53. Novartis Therapeutic Radioligands Product

Table 54. Novartis Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 55. Novartis Recent Development

Table 56. Lantheus Company Detail

Table 57. Lantheus Business Overview

Table 58. Lantheus Therapeutic Radioligands Product

Table 59. Lantheus Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 60. Lantheus Recent Development

Table 61. Aurobindo Pharma Company Detail

Table 62. Aurobindo Pharma Business Overview

Table 63. Aurobindo Pharma Therapeutic Radioligands Product

Table 64. Aurobindo Pharma Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 65. Aurobindo Pharma Recent Development

Table 66. Mundipharma Company Detail

Table 67. Mundipharma Business Overview

Table 68. Mundipharma Therapeutic Radioligands Product

Table 69. Mundipharma Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 70. Mundipharma Recent Development

Table 71. China Isotope & Radiation Company Detail

Table 72. China Isotope & Radiation Business Overview

Table 73. China Isotope & Radiation Therapeutic Radioligands Product

Table 74. China Isotope & Radiation Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 75. China Isotope & Radiation Recent Development

Table 76. Curium Pharmaceuticals Company Detail

Table 77. Curium Pharmaceuticals Business Overview

Table 78. Curium Pharmaceuticals Therapeutic Radioligands Product

Table 79. Curium Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 80. Curium Pharmaceuticals Recent Development

Table 81. Gilead Sciences Company Detail

Table 82. Gilead Sciences Business Overview

Table 83. Gilead Sciences Therapeutic Radioligands Product

Table 84. Gilead Sciences Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 85. Gilead Sciences Recent Development

Table 86. Clarity Pharmaceuticals Company Detail

Table 87. Clarity Pharmaceuticals Business Overview

Table 88. Clarity Pharmaceuticals Therapeutic Radioligands Product

Table 89. Clarity Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 90. Clarity Pharmaceuticals Recent Development

Table 91. Curasight Company Detail

Table 92. Curasight Business Overview

Table 93. Curasight Therapeutic Radioligands Product

Table 94. Curasight Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 95. Curasight Recent Development

Table 96. Nordic Nanovector Company Detail

Table 97. Nordic Nanovector Business Overview

Table 98. Nordic Nanovector Therapeutic Radioligands Product

Table 99. Nordic Nanovector Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 100. Nordic Nanovector Recent Development

Table 101. Philogen Company Detail

Table 102. Philogen Business Overview

Table 103. Philogen Therapeutic Radioligands Product

Table 104. Philogen Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 105. Philogen Recent Development

Table 106. RadioMedix Company Detail

Table 107. RadioMedix Business Overview

Table 108. RadioMedix Therapeutic Radioligands Product

Table 109. RadioMedix Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 110. RadioMedix Recent Development

Table 111. Telix Pharmaceuticals Company Detail

Table 112. Telix Pharmaceuticals Business Overview

Table 113. Telix Pharmaceuticals Therapeutic Radioligands Product

Table 114. Telix Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 115. Telix Pharmaceuticals Recent Development

Table 116. Orano Med Company Detail

Table 117. Orano Med Business Overview

Table 118. Orano Med Therapeutic Radioligands Product

Table 119. Orano Med Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 120. Orano Med Recent Development

Table 121. Actinium Pharmaceuticals Company Detail

Table 122. Actinium Pharmaceuticals Business Overview

Table 123. Actinium Pharmaceuticals Therapeutic Radioligands Product

Table 124. Actinium Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 125. Actinium Pharmaceuticals Recent Development

Table 126. Y-mAbs Therapeutics Company Detail

Table 127. Y-mAbs Therapeutics Business Overview

Table 128. Y-mAbs Therapeutics Therapeutic Radioligands Product

Table 129. Y-mAbs Therapeutics Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 130. Y-mAbs Therapeutics Recent Development

Table 131. Fusion Pharmaceuticals Company Detail

Table 132. Fusion Pharmaceuticals Business Overview

Table 133. Fusion Pharmaceuticals Therapeutic Radioligands Product

Table 134. Fusion Pharmaceuticals Revenue in Therapeutic Radioligands Business (2019-2024) & (US$ Million)

Table 135. Fusion Pharmaceuticals Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Therapeutic Radioligands Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Therapeutic Radioligands Market Share by Type: 2023 VS 2030

Figure 3. Beta-emitting Features

Figure 4. Targeted Alpha Therapy Features

Figure 5. Global Therapeutic Radioligands Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Therapeutic Radioligands Market Share by Application: 2023 VS 2030

Figure 7. Solid Tumor Case Studies

Figure 8. Non Hodgkin Lymphoma Case Studies

Figure 9. Therapeutic Radioligands Report Years Considered

Figure 10. Global Therapeutic Radioligands Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 11. Global Therapeutic Radioligands Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Therapeutic Radioligands Market Share by Region: 2023 VS 2030

Figure 13. Global Therapeutic Radioligands Market Share by Players in 2023

Figure 14. Global Top Therapeutic Radioligands Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Radioligands as of 2023)

Figure 15. The Top 10 and 5 Players Market Share by Therapeutic Radioligands Revenue in 2023

Figure 16. North America Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 17. North America Therapeutic Radioligands Market Share by Country (2019-2030)

Figure 18. United States Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. Canada Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Europe Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Therapeutic Radioligands Market Share by Country (2019-2030)

Figure 22. Germany Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. France Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. U.K. Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Italy Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Russia Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Nordic Countries Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Asia-Pacific Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Therapeutic Radioligands Market Share by Region (2019-2030)

Figure 30. China Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Japan Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. South Korea Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Southeast Asia Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. India Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Australia Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Latin America Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Therapeutic Radioligands Market Share by Country (2019-2030)

Figure 38. Mexico Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Brazil Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Middle East & Africa Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Therapeutic Radioligands Market Share by Country (2019-2030)

Figure 42. Turkey Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Saudi Arabia Therapeutic Radioligands Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Bayer Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 45. Novartis Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 46. Lantheus Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 47. Aurobindo Pharma Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 48. Mundipharma Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 49. China Isotope & Radiation Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 50. Curium Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 51. Gilead Sciences Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 52. Clarity Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 53. Curasight Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 54. Nordic Nanovector Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 55. Philogen Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 56. RadioMedix Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 57. Telix Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 58. Orano Med Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 59. Actinium Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 60. Y-mAbs Therapeutics Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 61. Fusion Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Business (2019-2024)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions